Interim results from a large multinational extension trial (guardian(™) 2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A

Affiliations

• ¹ The University of Iowa Carver College of Medicine, Iowa City, IA, USA. steven-lentz@uiowa.edu.
• ² HEMORIO, Rio De Janeiro, Brazil.
• ³ School of Medicine, University of Belgrade, University Children's Hospital, Belgrade, Serbia.
• ⁴ Department of Hematology/Oncology, Emory University School of Medicine, Atlanta, GA, USA.
• ⁵ Novo Nordisk A/S, Soeborg, Denmark.
• ⁶ National Hemophilia Center, Chaim Sheba Medical Center, Tel Aviv University, Ramat-Gan, Israel.
• ⁷ Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany.
• ⁸ IHTC 'Claudio L.P. Correa', INCT do Sangue Hemocentro UNICAMP, University of Campinas, Sao Paulo, Brazil.
• ⁹ The Hemophilia Center, Oregon Health & Science University, Portland, OR, USA.
• ¹⁰ Clinic of Hematology, Clinical Center of Vojvodina, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
• ¹¹ Department of Laboratory Medicine, Tokyo Medical University, Tokyo, Japan.
• ¹² Hannover Medical School, Hannover, Germany.
• ¹³ Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital Policlinico, Milan, Italy.